EUVIMEDEUVIMED entdecken
Open Access

Immunological Evaluation of mRNA‐LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS‐CoV‐2

Feroza Begum, Md Hasan Mallik, Subhadip Ghora, Upasana Ray

Biotechnology Journal · 2026

DOI: 10.1002/biot.70294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Feroza Begum und 3 weiteren Autor:innen. Beteiligte Einrichtung: CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata, West Bengal, India. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSIR, Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of SARS‐CoV‐2 necessitates next‐generation vaccine strategies targeting conserved viral elements to ensure broad and durable protection. In this study, we designed and evaluated novel mRNA‐based vaccines encoding conserved domains of SARS‐CoV‐2, including the spike S2 subunit, NSP3 Macrodomain I (Mac I), and papain‐like protease (PLpro). These mRNAs were synthesized, cloned, and encapsulated into lipid nanoparticles (LNPs) with 70%–80% efficiency and favorable physicochemical properties. In vitro characterization showed efficient antigen expression with 60%–80% cell survival. Immunization of BALB/c mice induced strong humoral responses, particularly against S2 and Mac I, marked by IgG titers, class switching, and durable antibody presence up to 84 days post‐booster. PLpro elicited minimal antibody responses, likely due to limited stability or intrinsic low immunogenicity. Combinatorial LNPs encoding multiple antigens maintained robust expression and elicited comparable immune responses despite dose splitting. Anti‐S2 antibodies effectively inhibited spike protein uptake in vitro. Importantly, the selected antigenic regions exhibited high sequence conservation across major SARS‐CoV‐2 variants, underscoring their broad‐spectrum vaccine potential. These findings support further development of domain‐targeted, multi‐antigen mRNA vaccines to enhance cross‐variant protection and T‐cell‐mediated immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesSpike Glycoprotein, CoronavirusCOVID-19AnimalsMice, Inbred BALB CMiceFemaleRNA, MessengerAntibodies, ViralHumansProtein DomainsNanoparticlesVaccines, SyntheticViral Nonstructural ProteinsmRNA VaccinesNanovaccinesLipidsLiposomes

Substanzen

COVID-19 VaccinesSpike Glycoprotein, CoronavirusRNA, MessengerAntibodies, Viralspike protein, SARS-CoV-2Lipid NanoparticlesVaccines, SyntheticViral Nonstructural ProteinsmRNA VaccinesNanovaccines

Autor:innen und Institutionen

  • CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata, West Bengal, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.

Förderung

  • CSIR
  • Council of Scientific and Industrial Research, India

Zitieren

APA

Begum, F., Mallik, M. H., Ghora, S., & Ray, U. (2026). Immunological Evaluation of mRNA‐LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS‐CoV‐2. Biotechnology Journal. https://doi.org/10.1002/biot.70294

Vancouver

Begum F, Mallik MH, Ghora S, Ray U. Immunological Evaluation of mRNA‐LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS‐CoV‐2. Biotechnology Journal. 2026. doi:10.1002/biot.70294

BibTeX
@article{Begum2026,
  author = {Begum, Feroza and Mallik, Md Hasan and Ghora, Subhadip and Ray, Upasana},
  title = {Immunological Evaluation of mRNA‐LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS‐CoV‐2},
  journal = {Biotechnology Journal},
  year = {2026},
  doi = {10.1002/biot.70294}
}
Kostenlos starten →